Tier 2 — strong
Targeting SIRT6: the design and therapeutic implications of activators and inhibitors
Bioorganic & Medicinal Chemistry
2026
142:118781
Bibliography
- PubMed
- PMID 42628273
- Funding
- Supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0507700 and 2023ZD0507704), National Natural Science Foundation of China grants 22477070 and 22377068, Taishan Scholar Programme of Shandong Province, Key R&D Program of Shandong Province, and Shandong Provincial Youth Innovation Team Development Program.
- Competing interests
- The authors declared no known competing financial interests or personal relationships that could have appeared to influence the work.
Study snapshot
| Design | |
|---|---|
| Model | |
| Sample | |
| Intervention | |
| Duration | |
| Endpoints |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- SIRT6 Therapeutics: Gene Therapy, Activators, Inhibitors & PeptidesSIRT6 can be targeted with gene therapy, allosteric activators, inhibitors and experimental peptides. See AAV research, MDL-800, UBCS039, forvisirvat and why inhibition...Read analysis
- SIRT6 Activator: Natural Compounds, Synthetic Drugs & Human EvidenceSIRT6 activators include natural compounds such as cyanidin and fucoidan, synthetic research molecules such as MDL-800, and clinical-stage forvisirvat. Here is what...Read analysis
- SIRT6 Mechanism & Structure: Catalytic Activities, Regulation and ActivatorsSIRT6 has one active site and three distinct enzymatic activities. Here's how the enzyme is built, how it works, and what activators...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
